Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab vs methylprednisolone for drug eruptions in adults
ChiCTR2200067227Phase 4Not yet recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in toxicoderma (cADR) and severe cutaneous adverse reactions (SCAR) (2 arms), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoints: IGA score multiplied by lesion area reduction value, Incidence rate of adverse events and 1 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
03
Conditions
toxicoderma (cADR)severe cutaneous adverse reactions (SCAR)
Beyond the preview
Go deeper on ChiCTR2200067227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067227.